Newly released data from Pfizer/BioNTech’s ongoing study of their COVID-19 vaccine suggests it is effective at preventing serious symptoms and death at least six months after vaccination. The ...

A new mRNA vaccine against the flu has proven itself more effective than existing vaccines in a new clinical trial. The ...

An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

Erin Morgan, a registered nurse, administers the Pfizer COVID-19 vaccine to 14-year-old Zach Bilyj of Wake Forest, North Carolina, during a vaccination clinic. Kids ages 12 and up are eligible for the ...

In a recent study published in The Lancet Regional Health Western Pacific, researchers compare the immunogenicity, reactogenicity, and safety of a half-dose Pfizer-BioNTech BNT162b2 coronavirus ...

Shares in video-call software Zoom plunged by around 15 percent this morning as news broke about a promising COVID-19 vaccine candidate. Pharmaceutical companies Pfizer and BioNTech said today that ...

Pfizer announced Monday that its COVID-19 vaccine candidate has been 90% effective. In a press release, the company said that in Phase 3 trials, the vaccine has proven to promote a vaccine efficacy ...

Smaller doses of Pfizer’s COVID-19 vaccine appear safe and more than 90% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released by the company on ...

NEW YORK (Reuters) - Pfizer Inc's experimental pill for rheumatoid arthritis appeared to be effective and well-tolerated in a mid-stage clinical study, the drugmaker said. The drug, known as ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...